𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Aberrant methylation of Reprimo in human malignancies

✍ Scribed by Takao Takahashi; Makoto Suzuki; Hisayuki Shigematsu; Narayan Shivapurkar; Chinyere Echebiri; Masaharu Nomura; Victor Stastny; Meena Augustus; Chew-Wun Wu; Ignacio I. Wistuba; Stephen J. Meltzer; Adi F. Gazdar

Book ID
102862168
Publisher
John Wiley and Sons
Year
2005
Tongue
French
Weight
683 KB
Volume
115
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Reprimo is a new candidate mediator of p53‐mediated cell cycle arrest at the G~2~ phase. Loss of Reprimo gene expression accompanied by its promoter methylation was identified in pancreatic and lung cancers. Our aim was to examine the methylation status of Reprimo in a broad range of cancers. We examined Reprimo expression by RT‐PCR and the DNA methylation status of the Reprimo promoter by MSP in 39 tumor cell lines. Loss or downregulation of Reprimo expression was frequent (62%), and we confirmed that transcriptional repression of Reprimo was caused by hypermethylation (overall concordance 92%). Treatment of expression‐negative cells with 5‐aza‐2′‐deoxycytidine restored Reprimo expression. We then examined aberrant methylation of Reprimo in 645 tumors representing 16 tumor types. Promoter methylation of Reprimo was found in 79% of gastric cancers, 62% of gallbladder cancers, 57% of lymphomas, 56% of colorectal cancers, 40% of esophageal adenocarcinomas, 37% of breast cancers and 31% of leukemias. Methylation frequencies in ovarian cancers, bladder cancers, cervical cancers, brain tumors, malignant mesotheliomas and pediatric tumors were lower (0–20%). Reprimo methylation was rarely detected in nonmalignant tissues (0–11%) except for gastric epithelia. While colorectal polyps were also frequently methylated (27%), chronic cholecystitis samples were infrequently methylated (4%). Furthermore, we failed to identify Reprimo mutation in colorectal and gastric cancer cell lines and 50 primary colorectal cancers. Aberrant methylation of Reprimo with loss of expression is a common event and may contribute to the pathogenesis of some types of human malignancy. © 2005 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Aberrant methylation of Reprimo correlat
Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma
✍ Norihiro Sato; Noriyoshi Fukushima; Hiroyuki Matsubayashi; Christine A. Iacobuzi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB 👁 1 views

## Abstract ## BACKGROUND The p53‐dependent G2/M checkpoint plays a key role in the maintenance of genomic integrity, thereby protecting cells from neoplastic progression. __Reprimo__, a gene involved in the p53‐induced G2 cell cycle arrest, has been recently identified as a novel target for aberr

Aberrant methylation of HIN-1 (high in n
Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies
✍ Hisayuki Shigematsu; Makoto Suzuki; Takao Takahashi; Kuniharu Miyajima; Shinichi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 175 KB

HIN-1 (high in normal-1) is a putative cytokine with growth inhibitory activities and is downregulated by aberrant methylation in breast cancers. We studied HIN-1 methylation status in many types of adult and pediatric malignancies and cell lines. We examined the expression of HIN-1 mRNA in 52 cell

Mutations and aberrant DNA methylation o
Mutations and aberrant DNA methylation of the PROX1 gene in hematologic malignancies
✍ Hirokazu Nagai; Yinghua Li; Sonoko Hatano; Ohno Toshihito; Masayuki Yuge; Etsuro 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 324 KB

## Abstract The homeobox gene __PROX1__ is related to the __Drosophila prospero__ gene, which is expressed in the developing central nervous system and lens‐secreting cone cells. We found that the __PROX1__ gene had missense and nonsense mutations in 4 of 29 hematologic cell lines analyzed. Decreas